This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Aveo Pharma: 'Crossover' Ate My Kidney Cancer Drug Survival Benefit

Stocks in this article: AVEOPFEONXXGSK

Tivozanib is under FDA review, with an approval decision expected by July 28.

To bolster the supportive case for approval, Aveo is also expected to point to other analyses from the phase III trial supporting tivozanib's efficacy in kidney cancer patients. Treatment with tivozanib following Nexavar resulted in a median progression-free survival of 8.4 months and a tumor response rate of 13%. Tivozanib-treated patients reported fewer side effects dose reductions than patients treated with Nexavar, but this did not translate into a significant difference in quality of life scores between the two drugs.

The median overall survival of 28.8 months reported by tivozanib-treated patients is similar to survival rates of competing kidney cancer drugs. In a recent study comparing Glaxo's Votrient to Pfizer's Sutent, median overall survival was 28.4 months and 29.3 months, respectively. Aveo has only compared tivozanib directly against Nexavar but is conducting another study right now that pits tivozanib against Sutent.

Multiple presentations of data from the tivozanib phase III study in kidney cancer are being presented later this week at the American Society of Clinical Oncology Genitourinary Cancers Symposium.

If FDA approves tivoazanib, it will be the ninth drug marketed for kidney cancer and the fifth drug to share a similar mechanism of action. Sutent has been the market-leading kidney cancer drug but has recently lost ground to Votrient.

-- Reported by Adam Feuerstein in Boston.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.
2 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,562.37 +162.70 0.99%
S&P 500 1,928.79 +24.78 1.30%
NASDAQ 4,387.4840 +71.41 1.65%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs